US Patent 4,874,794: Claim Scope, Expiration, and Docosanol Patent Landscape

US Patent 4,874,794 covers a method of treating virus-induced and inflammatory diseases of the skin or membranes by applying a topical composition containing docosanol, tetracosanol, hexacosanol, or combinations of those aliphatic alcohols. The patent does not claim docosanol as a chemical compound, a standalone composition, or a manufacturing process.

The patent was granted on October 17, 1989, and its enforceable term has expired. On that basis, US Patent 4,874,794 no longer creates a US patent barrier to commercial use of docosanol or the claimed topical treatment method. Its historical importance is that it provided the foundational method-of-use protection associated with topical docosanol treatment for herpes labialis.

What does US Patent 4,874,794 cover?

The patent covers topical treatment using one or more of three long-chain aliphatic alcohols:

Claimed alcohol	Common chemical description	Relevance
Docosanol	1-docosanol, behenyl alcohol, C22 alcohol	Principal commercial active ingredient
Tetracosanol	C24 aliphatic alcohol	Alternative claimed active
Hexacosanol	C26 aliphatic alcohol	Alternative claimed active

Claim 1 requires all of the following:

A method of treating a virus-induced or inflammatory disease.
The disease must affect skin or a membrane.
The patient must be human or animal.
The composition must be applied topically to the affected tissue.
The composition must contain one or more of docosanol, tetracosanol, and hexacosanol.
The identified alcohol or alcohols must be present at 0.1% to 25% by weight.
The composition must use a physiologically compatible carrier.

Claim 2 narrows the concentration range to approximately 1% to 5% by weight.

The claims are method claims. They do not expressly cover every product containing docosanol, nor do they claim every use of docosanol.

How broad is claim 1 of US 4,874,794?

Claim 1 is broad in disease category and active-ingredient selection but limited by its treatment method and formulation requirements.

Disease scope

The phrase "virus-induced and inflammatory diseases of skin and membranes" potentially reaches a wide range of indications, including:

Herpes simplex lesions, including cold sores
Viral lesions of mucosal tissue
Other virus-associated cutaneous conditions
Inflammatory disorders affecting skin or membranes

The claim does not limit treatment to herpes labialis. A product could fall within the claim based on treatment of another qualifying viral or inflammatory condition if the other claim elements were met.

The claim also does not specify a particular mechanism of action, formulation vehicle, dosage frequency, treatment duration, or disease severity.

Active-ingredient scope

The claim covers:

Docosanol alone
Tetracosanol alone
Hexacosanol alone
Mixtures containing two or more of those alcohols

It does not expressly cover every fatty alcohol. A formulation containing octanol, cetyl alcohol, stearyl alcohol, or another non-listed alcohol would not literally satisfy the active-ingredient limitation unless a court applied an equivalents analysis.

Concentration scope

Claim 1 covers a concentration from 0.1% to 25% by weight. Claim 2 covers approximately 1% to 5%.

The ranges create several practical distinctions:

Product concentration	Claim 1	Claim 2
Below 0.1%	Outside literal range	Outside
0.1% to below 1%	Within	Outside
Approximately 1% to 5%	Within	Within
Above 5% to 25%	Within	Outside claim 2
Above 25%	Outside literal range	Outside

The commercial 10% docosanol cream associated with Abreva would fall within claim 1's concentration range but outside the narrower concentration range of claim 2.

Carrier requirement

The composition must contain a "physiologically compatible carrier." That term would ordinarily encompass topical pharmaceutical vehicles that are tolerated by skin or mucosal tissue, such as creams, lotions, ointments, emulsions, gels, or comparable carriers.

The claim does not require a specific excipient. It also does not prescribe a particular pH, particle size, preservative, emulsifier, penetration enhancer, or delivery system.

What does the "consisting of" language exclude?

The phrase "a composition consisting of one or more of" the three named alcohols is important. "Consisting of" is generally treated as a closed transitional phrase. It excludes additional ingredients that materially alter the claimed composition, while permitting ingredients that do not change the basic and novel characteristics of the composition.

The practical result is:

A carrier and conventional excipients can be present because the claim expressly requires a physiologically compatible carrier.
Additional active antiviral or anti-inflammatory ingredients may create a claim-scope issue.
A combination product containing docosanol plus another pharmacologically active ingredient would require careful analysis.
An inactive preservative, stabilizer, emulsifier, fragrance, or viscosity modifier would not necessarily avoid the claim.
A product containing only a non-listed aliphatic alcohol would be outside the literal active-ingredient limitation.

Whether a particular co-ingredient is excluded depends on claim construction, the patent specification, prosecution history, and the ingredient's effect on the composition.

How does claim 2 differ from claim 1?

Claim 2 is a dependent concentration claim. It incorporates all limitations of claim 1 and narrows the alcohol concentration to approximately 1% to 5%.

Claim 2 therefore has a narrower literal scope than claim 1. Its potential advantages would have been:

A closer relationship to lower-strength formulations
A more specific formulation range
Possible fallback protection if broader claim 1 were challenged
Greater relevance to products using low concentrations of docosanol or related alcohols

A 10% docosanol product could not literally infringe claim 2 based on concentration, but it could have fallen within claim 1 while that claim remained enforceable.

When did US Patent 4,874,794 lose exclusivity?

US Patent 4,874,794 is expired.

Event	Date
US filing	May 27, 1988
Earliest claimed priority	May 29, 1987
Patent grant	October 17, 1989
Patent term under applicable pre-1995 rules	17 years from grant
Expiration	October 17, 2006

The patent was issued under the pre-Uruguay Round Agreements Act patent-term regime. For patents in that category, the governing term was generally 17 years from grant, subject to specific statutory adjustments and terminal-disclaimer issues. The published patent record identifies October 17, 2006, as the expiration date. [1]

The patent therefore cannot support a current US infringement action based solely on the claims quoted by the user.

What was the commercial significance of the patent?

The patent provided method-of-use protection for topical long-chain aliphatic alcohol therapy before docosanol became a widely marketed cold-sore product.

The principal commercial product associated with this technology is Abreva, a 10% docosanol cream marketed in the United States for shortening the duration and severity of cold-sore symptoms. The product's active ingredient is docosanol, not tetracosanol or hexacosanol. The historical relevance of US 4,874,794 is strongest for docosanol treatment of herpes labialis and related topical viral lesions.

The patent did not by itself create a permanent product monopoly because:

It did not claim the docosanol molecule as a chemical entity.
It did not claim all docosanol formulations.
It did not claim all uses of docosanol.
It expired before the current generic and OTC competition period.
Its claims were limited to a particular treatment method and concentration range.

What is the FDA and Orange Book status of docosanol?

Docosanol is marketed in the United States as an over-the-counter topical product for cold sores. Abreva is labeled as docosanol 10% cream. FDA labeling identifies the product for treatment of cold sores and fever blisters on the face or lips. [2]

Orange Book status

US Patent 4,874,794 is not an active Orange Book patent listing that currently blocks approval of a generic product. Its term expired in 2006.

The principal regulatory points are:

Docosanol 10% cream has been marketed as an OTC drug product.
The product is associated with an FDA-approved drug application and OTC labeling history.
The expired patent does not support a current Paragraph IV challenge.
A company seeking approval or marketing of a competing product must address the applicable FDA pathway, product quality requirements, labeling, manufacturing controls, and any other unexpired intellectual-property rights.
An expired method patent does not eliminate formulation, process, trademark, trade-dress, or regulatory obligations.

The Orange Book primarily identifies patents and exclusivity associated with approved prescription and certain approved drug products. OTC marketing status and abbreviated approval mechanisms can differ from the standard prescription-generic framework. [3]

Were Paragraph IV challenges available for US 4,874,794?

Paragraph IV litigation is relevant when a patent is listed for an approved drug application and an ANDA applicant certifies that the patent is invalid, unenforceable, or not infringed.

US Patent 4,874,794 is now expired, so it cannot generate a current Paragraph IV certification or 30-month stay. Historically, a Paragraph IV challenge could have been relevant only while:

The patent was listed for the relevant drug application;
The patent had not expired;
The proposed product was submitted through an ANDA or comparable pathway; and
The patent claims were implicated by the proposed product or use.

Because the patent expired in 2006, present-day market entry does not require a Paragraph IV strategy directed to this patent.

What patent landscape surrounds docosanol and topical antiviral creams?

The relevant landscape is broader than US 4,874,794. A complete freedom-to-operate review for a docosanol product should separate five categories.

1. Method-of-use patents

These cover treatment of a specific disease, lesion, or patient population. US 4,874,794 is an example. Later patents could attempt to narrow:

Treatment of herpes labialis
Reduction of lesion duration
Treatment before lesion formation
Specific dosing schedules
Use in selected patient groups
Combination therapy

The expired patent does not prevent later patents from covering a different, narrower method if those claims satisfy novelty and non-obviousness requirements.

2. Formulation patents

Formulation patents can cover:

A particular docosanol concentration
Cream or emulsion systems
Solubilization or dispersion techniques
Particle-size distributions
Preservative systems
Penetration enhancers
Enhanced skin residence
Improved stability
Packaging and dosing configurations

A competitor using 10% docosanol could avoid the expired method patent yet encounter a later formulation claim if its product uses the same claimed excipient system or manufacturing parameters.

3. Manufacturing patents

Manufacturing protection may cover:

Purification of docosanol
Hydrogenation or reduction steps
Removal of unreacted fatty alcohols
Control of oxidation products
Crystallization
Scale-up and batch consistency
Manufacture of a stable cream or emulsion

Manufacturing claims are especially relevant where the active ingredient is difficult to purify or where a formulation depends on a defined impurity profile.

4. Combination-product patents

A product containing docosanol with another antiviral, anesthetic, analgesic, anti-inflammatory, or barrier-repair agent could implicate claims directed to a combination therapy. The closed language in claim 1 makes the treatment of additional active ingredients a claim-construction issue for the expired patent, but later patents may expressly claim combinations.

5. Non-patent commercial rights

A generic or private-label product can face non-patent barriers, including:

Abreva trademarks
Trade dress
Product-name restrictions
OTC labeling requirements
Manufacturing and quality standards
Distributor and retailer requirements
Consumer-protection rules

These rights do not extend the term of US 4,874,794.

Which companies are challenging or competing with Abreva?

No current Paragraph IV challenge to US 4,874,794 is commercially meaningful because the patent expired in 2006.

Competition is more likely to arise from:

Private-label docosanol 10% creams
Store-brand cold-sore products
Products using alternative actives such as benzyl alcohol
Prescription antivirals such as acyclovir, valacyclovir, and penciclovir
Non-drug barrier products and symptomatic treatments

Docosanol competes primarily on OTC availability and topical use. Prescription nucleoside analogues compete on physician-directed treatment, systemic exposure, and treatment of broader herpes infections.

How does the patent estate compare with competing antiviral products?

Product category	Typical active	Principal protection issues	Current competitive position
Docosanol cream	Docosanol	Expired foundational method patent; later formulation and trademark rights	OTC cold-sore treatment
Acyclovir cream or ointment	Acyclovir	Historical compound, formulation, and use patents largely expired in the US	Prescription or OTC-dependent by product
Valacyclovir tablets	Valacyclovir	Historical composition and use patents largely expired	Generic prescription competition
Penciclovir cream	Penciclovir	Product-specific formulation and use rights	Topical prescription competition
Benzyl alcohol cold-sore products	Benzyl alcohol	Formulation, labeling, and trademark issues	Alternative OTC treatment

US 4,874,794 is weaker than a compound patent from a claim-breadth perspective because it requires a particular use and delivery route. It was still commercially valuable because it covered the intended topical treatment method across a broad concentration range.

What generic launch risks remain after patent expiration?

The patent-expiration risk is low for the specific claims quoted. A company can generally market a docosanol topical product without infringing US 4,874,794, provided that no other active patent claims are implicated.

Remaining risks include:

Later formulation patents
Manufacturing-process patents
Combination-product patents
Patent rights in jurisdictions outside the United States
Trademark and trade-dress claims
FDA labeling or monograph compliance
Product-quality and stability failures
Misbranding or unsupported therapeutic claims

A company should not treat expiration of the foundational patent as automatic clearance for every docosanol product. Patent risk shifts from the basic treatment concept to product-specific formulation, process, and commercial implementation.

What is the geographic coverage of US 4,874,794?

US 4,874,794 has territorial effect only in the United States. It does not establish protection in Canada, Europe, Japan, China, or other markets.

The relevant geographic conclusions are:

US rights: expired.
Foreign rights: must be reviewed by patent family and national phase.
Foreign expiration: may differ by filing date, grant date, patent-term rules, supplementary protection, or abandonment.
International product launch: requires a jurisdiction-by-jurisdiction search.
US freedom to operate: cannot be inferred from foreign patent status.

The patent's US expiration does not establish that all corresponding foreign patents expired on the same date.

How strong was the patent estate?

For its time, the patent had useful commercial scope but limited structural breadth.

Strength factor	Assessment
Chemical compound protection	Weak; no compound claim
Method-of-use breadth	Strong within topical skin and membrane treatment
Concentration coverage	Broad at 0.1% to 25%
Formulation specificity	Limited
Manufacturing protection	None in the quoted claims
Combination-product protection	Limited by "consisting of" language
Current enforceability	None; expired
Current blocking value	None for the expired claims

The most important limitation is that the patent protected use, not the underlying molecule. Once the patent expired, competitors could use docosanol in topical products without violating these claims.

Key Takeaways

US Patent 4,874,794 covers topical treatment of virus-induced and inflammatory skin or membrane diseases.
The claimed actives are docosanol, tetracosanol, and hexacosanol.
Claim 1 covers 0.1% to 25% by weight in a physiologically compatible carrier.
Claim 2 narrows the range to approximately 1% to 5%.
The commercial 10% docosanol cream falls within claim 1 but not claim 2.
The patent is a method-of-use patent, not a compound, formulation, or manufacturing patent.
The patent expired on October 17, 2006.
It cannot support a current Paragraph IV challenge, 30-month stay, or US infringement claim.
Current risk must be assessed against later formulation, manufacturing, combination, trademark, and regulatory rights.
Foreign patent status cannot be inferred from the US expiration date.

FAQs About US Patent 4,874,794 and Docosanol

Does US Patent 4,874,794 cover Abreva 10% cream?

Historically, a 10% docosanol cream could have fallen within claim 1 because the claim covers docosanol concentrations from 0.1% to 25%. The patent is expired and no longer blocks the product.

Can a company sell a generic docosanol cream in the United States?

The expired patent does not prevent sale of a generic or private-label docosanol cream. The product must still satisfy FDA requirements and avoid infringement of later patents or non-patent commercial rights.

Is docosanol protected by a composition-of-matter patent?

US Patent 4,874,794 does not claim docosanol as a chemical compound. It claims a topical treatment method using docosanol or specified related alcohols.

Does the patent cover oral docosanol?

No. The claims require topical application to inflamed skin or a membrane. Oral administration is outside the literal scope of the quoted claims.

Does the patent cover docosanol concentrations above 25%?

No. A concentration above 25% is outside the literal concentration range in claim 1. Other patents or a doctrine-of-equivalents theory would require separate analysis.

References

United States Patent and Trademark Office. (1989). U.S. Patent No. 4,874,794: Use of aliphatic alcohols for treatment of virus-induced and inflammatory diseases. https://patents.google.com/patent/US4874794
U.S. Food and Drug Administration. (n.d.). Abreva (docosanol) cream labeling and drug information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0428642	⤷ Start Trial	300354	Netherlands	⤷ Start Trial
European Patent Office	0428642	⤷ Start Trial	07C0081	France	⤷ Start Trial
European Patent Office	0428642	⤷ Start Trial	57/2007	Austria	⤷ Start Trial
Austria	95060	⤷ Start Trial
Austria	96662	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,874,794

Summary for Patent: 4,874,794